



Personalized Therapy for Basic and Translational in Upper Gastrointestinal Cancer

Guest Editor:

Dr. Valeria Merz

1. Digestive Molecular Clinical
Oncology Research Unit,
Università degli Studi di Verona,
37134 Verona, Italy
2. Medical Oncology Unit, Santa
Chiara Hospital, 38122 Trento,
Italy

Deadline for manuscript
submissions:

20 February 2025

Message from the Guest Editor

Upper gastrointestinal cancer, encompassing gastroesophageal, pancreatic and hepatobiliary tract cancer, is one of the most common cancers worldwide, with high morbidity and mortality. In recent years, from the beginning of diagnosis to the development of new surgical techniques to the most innovative medical therapies, the treatment of these tumors has changed profoundly. Furthermore, today's developments in translational oncology allow for personalized treatments based on molecular profiling and genetic tools. Interestingly, an emerging key role of microbiota both in carcinogenesis and treatment response has been highlighted in the last few years.

Evolving strategies for early cancer detection and treatment have improved overall survival. Gastrointestinal cancer surgeries, such as laparoscopy and robotic resection, are still effective treatments. In addition to traditional chemotherapy, targeted therapy and immunotherapy have further improved the treatment and survival rate of patients with upper gastrointestinal cancer, providing new opportunities for personalized cancer treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)